Lb Pharmaceuticals (LBRX) Research & Development (2024 - 2026)
Lb Pharmaceuticals' quarterly Research & Development came in at $14.6 million in Q1 2026, up 328.09% year-on-year from $3.4 million in Q1 2025, and up 72.64% quarter-over-quarter from $8.5 million in Q4 2025.
Lb Pharmaceuticals has reported Research & Development for 3 years, with the latest figure at $14.6 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 328.09% year-over-year to $14.6 million; the trailing twelve-month figure through Mar 2026 stood at $29.0 million (changed N/A YoY), and the FY2025 full-year result was $16.7 million, down 67.28% from the prior year.
- Research & Development for Q1 2026 stood at $14.6 million, up from $8.5 million in the prior quarter.
- The five-year high for Research & Development was $14.6 million in Q1 2026, with the low at $376000.0 in Q4 2024.
- Average Research & Development over 3 years is $6.7 million, with a median of $6.0 million recorded in 2025.
- Peak annual rise in Research & Development reached 2156.12% in 2025, while the deepest fall reached 77.32% in 2025.
- Tracing LBRX's Research & Development over 3 years: stood at $376000.0 in 2024, then surged by 2156.12% to $8.5 million in 2025, then jumped by 72.64% to $14.6 million in 2026.
- The last three Research & Development figures came in at $14.6 million (Q1 2026), $8.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Lb Pharmaceuticals | 789.92 Mn | 789.92 Mn | - | 14.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.65 Mn |
| Dec 31, 2025 | 8.48 Mn |
| Sep 30, 2025 | 2.42 Mn |
| Mar 31, 2025 | 3.42 Mn |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 10.66 Mn |